Research programme: anti-inflammatory therapeutics - Istesso
Latest Information Update: 28 Jul 2019
At a glance
- Originator University of Aberdeen
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in United Kingdom (PO)
- 29 Jun 2015 Preclinical trials in Rheumatoid arthritis in United Kingdom (PO)
- 07 Mar 2011 No development reported - Preclinical for Inflammation in United Kingdom (PO)